Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Coronavirus vaccine - Stemirna Therapeutics/Tongji University

Drug Profile

Coronavirus vaccine - Stemirna Therapeutics/Tongji University

Latest Information Update: 06 Apr 2020

At a glance

  • Originator Stemirna Therapeutics; Tongji University
  • Class RNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical COVID 2019 infections

Most Recent Events

  • 23 Mar 2020 Preclinical trials in COVID-2019 infections (Prevention) in China (parenteral) before March 2020

Development Overview

Introduction

A ribonucleic acid (mRNA) based vaccine to prevent COVID-19 infections is co-developed by Stemirna Therapeutics, Chinese Center for Disease Control and Prevention (CDC) and Tongji University. The vaccine uses mRNA technology and encodes surface proteins on corona virus, which can activates the immune response. Preclinical trials are underway in China.

Stemirna Therapeutics has mRNA synthesis platform, which is used for development of mRNA-based medicines for various indications. mRNA synthesis platform uses DNA templates to synthesize mRNA in vitro. Further template optimisation, codon optimisation in coding sequence and modified nucleotide used to improve translational efficiency of mRNA.

Drug Properties & Chemical Synopsis

  • Route of administration Parenteral
  • Formulation unspecified
  • Class RNA vaccines, Viral vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B (Viral Vaccines)

  • EPhMRA code

    J7E (Viral Vaccines)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - Prevention Preclinical China Parenteral / unspecified Stemirna Therapeutics, Tongji University 23 Mar 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Tongji University Originator China
Stemirna Therapeutics Originator China
Stemirna Therapeutics Owner China
Tongji University Owner China
National Institutes for food and drug Control Collaborator China
China Center for Disease Control and Prevention Collaborator China

Development History

Event Date Update Type Comment
23 Mar 2020 Phase Change - Preclinical Preclinical trials in COVID-2019 infections (Prevention) in China (parenteral) before March 2020 Updated 06 Apr 2020
Back to top